Search

Your search keyword '"Itoh, Kyogo"' showing total 1,034 results
Start Over Author "Itoh, Kyogo"
1,034 results on '"Itoh, Kyogo"'

2. Exploring the Potential of Humoral Immune Response to Commensal Bifidobacterium as a Biomarker for Human Health, including Both Malignant and Non-Malignant Diseases: A Perspective on Detection Strategies and Future Directions.

Author

Itoh, Kyogo and Matsueda, Satoko

Subjects
HUMORAL immunity, EMERGING infectious diseases, HUMAN biology, MOLECULAR mimicry, IMMUNE checkpoint inhibitors, CYTOTOXIC T cells
Abstract

In this comprehensive review, we explore the pivotal role of commensal Bifidobacterium (c-BIF) as potent non-self-antigens through antigenic mimicry, along with exploring the potential of humoral immune responses for both malignant and non-malignant disease. c-BIF, a predominant component of the human gut microbiome encompassing around 90% of the human genome, has emerged as a pivotal player in human biology. Over recent decades, there has been extensive research elucidating the intricate connections between c-BIF and various facets of human health, with particular emphasis on their groundbreaking impact on anti-cancer effects and the management of non-malignant diseases. The multifaceted role of c-BIF is explored, ranging from enhancing anti-tumor immunity to improving the efficacy of anti-cancer and anti-infectious disease strategies, and serving as predictive biomarkers for various diseases. Recent studies highlight not only c-BIF's promotion of anti-tumor immunity but also their role in enhancing the efficacy of immune checkpoint inhibitors. The review emphasizes the promising avenue of manipulating the gut microbiota, particularly c-BIF, for modulating cancer immunotherapy with targeted effects on tumor cells while minimizing harm to normal tissue. In the context of infectious and inflammatory diseases, the crucial role of c-BIFs in the management of COVID-19 symptoms is examined, emphasizing their impact on the severity of and immune response to COVID-19. Furthermore, c-BIF exhibits preventive and therapeutic effects on Human Papillomaviruses (HPV) and shows promise in improving inflammatory bowel diseases. The potential application of c-BIF as a biomarker for immunotherapy is explored, with a specific emphasis on its predictive and prognostic value in cancer. Suggestions are made regarding the use of humoral immune responses to cytotoxic T lymphocyte (CTL) epitope peptides that share motifs with c-BIF, proposing them as potential markers for predicting overall survival in diverse cancer patients. In conclusion, c-BIF emerges as a crucial and multifaceted determinant of human health, across anti-tumor immunity to infectious and inflammatory disease management. The manipulation of c-BIF and gut microbiota presents a promising avenue for advancing therapeutic strategies, particularly in the realm of cancer immunotherapy. Additionally, this review highlights the significance of c-BIF as potent non-self-antigens via antigenic mimicry, emphasizing the importance of robust humoral immune responses against c-BIF for preventing various diseases, including inflammatory conditions. Elevated levels of circulating antibodies against c-BIF in healthy individuals may serve as potential indicators of lower risks for malignant and non-malignant diseases. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

Author

Pagès, Franck, Mlecnik, Bernhard, Marliot, Florence, Bindea, Gabriela, Ou, Fang-Shu, Bifulco, Carlo, Lugli, Alessandro, Zlobec, Inti, Rau, Tilman T, Berger, Martin D, Nagtegaal, Iris D, Vink-Börger, Elisa, Hartmann, Arndt, Geppert, Carol, Kolwelter, Julie, Merkel, Susanne, Grützmann, Robert, Van den Eynde, Marc, Jouret-Mourin, Anne, Kartheuser, Alex, Léonard, Daniel, Remue, Christophe, Wang, Julia Y, Bavi, Prashant, Roehrl, Michael H A, Ohashi, Pamela S, Nguyen, Linh T, Han, SeongJun, MacGregor, Heather L, Hafezi-Bakhtiari, Sara, Wouters, Bradly G, Masucci, Giuseppe V, Andersson, Emilia K, Zavadova, Eva, Vocka, Michal, Spacek, Jan, Petruzelka, Lubos, Konopasek, Bohuslav, Dundr, Pavel, Skalova, Helena, Nemejcova, Kristyna, Botti, Gerardo, Tatangelo, Fabiana, Delrio, Paolo, Ciliberto, Gennaro, Maio, Michele, Laghi, Luigi, Grizzi, Fabio, Fredriksen, Tessa, Buttard, Bénédicte, Angelova, Mihaela, Vasaturo, Angela, Maby, Pauline, Church, Sarah E, Angell, Helen K, Lafontaine, Lucie, Bruni, Daniela, El Sissy, Carine, Haicheur, Nacilla, Kirilovsky, Amos, Berger, Anne, Lagorce, Christine, Meyers, Jeffrey P, Paustian, Christopher, Feng, Zipei, Ballesteros-Merino, Carmen, Dijkstra, Jeroen, van de Water, Carlijn, van Lent-van Vliet, Shannon, Knijn, Nikki, Mușină, Ana-Maria, Scripcariu, Dragos-Viorel, Popivanova, Boryana, Xu, Mingli, Fujita, Tomonobu, Hazama, Shoichi, Suzuki, Nobuaki, Nagano, Hiroaki, Okuno, Kiyotaka, Torigoe, Toshihiko, Sato, Noriyuki, Furuhata, Tomohisa, Takemasa, Ichiro, Itoh, Kyogo, Patel, Prabhu S, Vora, Hemangini H, Shah, Birva, Patel, Jayendrakumar B, Rajvik, Kruti N, Pandya, Shashank J, Shukla, Shilin N, Wang, Yili, Zhang, Guanjun, Kawakami, Yutaka, Marincola, Francesco M, Ascierto, Paolo A, Sargent, Daniel J, Fox, Bernard A, and Galon, Jérôme

Published
2018
Full Text
View/download PDF

9. Data from Phase II Study of Personalized Peptide Vaccination for Previously Treated Advanced Colorectal Cancer

Author

Kibe, Shiro, primary, Yutani, Shigeru, primary, Motoyama, Satoru, primary, Nomura, Takanobu, primary, Tanaka, Natsuki, primary, Kawahara, Akihiko, primary, Yamaguchi, Tomohiko, primary, Matsueda, Satoko, primary, Komatsu, Nobukazu, primary, Miura, Masatomo, primary, Hinai, Yudai, primary, Hattori, Satoshi, primary, Yamada, Akira, primary, Kage, Masayoshi, primary, Itoh, Kyogo, primary, Akagi, Yoshito, primary, and Sasada, Tetsuro, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Methods from Phase II Study of Personalized Peptide Vaccination for Previously Treated Advanced Colorectal Cancer

Author

Kibe, Shiro, primary, Yutani, Shigeru, primary, Motoyama, Satoru, primary, Nomura, Takanobu, primary, Tanaka, Natsuki, primary, Kawahara, Akihiko, primary, Yamaguchi, Tomohiko, primary, Matsueda, Satoko, primary, Komatsu, Nobukazu, primary, Miura, Masatomo, primary, Hinai, Yudai, primary, Hattori, Satoshi, primary, Yamada, Akira, primary, Kage, Masayoshi, primary, Itoh, Kyogo, primary, Akagi, Yoshito, primary, and Sasada, Tetsuro, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Table S5 from Phase II Study of Personalized Peptide Vaccination for Previously Treated Advanced Colorectal Cancer

Author

Kibe, Shiro, primary, Yutani, Shigeru, primary, Motoyama, Satoru, primary, Nomura, Takanobu, primary, Tanaka, Natsuki, primary, Kawahara, Akihiko, primary, Yamaguchi, Tomohiko, primary, Matsueda, Satoko, primary, Komatsu, Nobukazu, primary, Miura, Masatomo, primary, Hinai, Yudai, primary, Hattori, Satoshi, primary, Yamada, Akira, primary, Kage, Masayoshi, primary, Itoh, Kyogo, primary, Akagi, Yoshito, primary, and Sasada, Tetsuro, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure S2 from Phase II Study of Personalized Peptide Vaccination for Previously Treated Advanced Colorectal Cancer

Author

Kibe, Shiro, primary, Yutani, Shigeru, primary, Motoyama, Satoru, primary, Nomura, Takanobu, primary, Tanaka, Natsuki, primary, Kawahara, Akihiko, primary, Yamaguchi, Tomohiko, primary, Matsueda, Satoko, primary, Komatsu, Nobukazu, primary, Miura, Masatomo, primary, Hinai, Yudai, primary, Hattori, Satoshi, primary, Yamada, Akira, primary, Kage, Masayoshi, primary, Itoh, Kyogo, primary, Akagi, Yoshito, primary, and Sasada, Tetsuro, primary

Published
2023
Full Text
View/download PDF

14. Sapplemental Table 1 from An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy

Author

Noguchi, Masanori, primary, Matsumoto, Kazumasa, primary, Uemura, Hirotsugu, primary, Arai, Gaku, primary, Eto, Masatoshi, primary, Naito, Seiji, primary, Ohyama, Chikara, primary, Nasu, Yasutomo, primary, Tanaka, Masatoshi, primary, Moriya, Fukuko, primary, Suekane, Shigetaka, primary, Matsueda, Satoko, primary, Komatsu, Nobukazu, primary, Sasada, Tetsuro, primary, Yamada, Akira, primary, Kakuma, Tatsuyuki, primary, and Itoh, Kyogo, primary

Published
2023
Full Text
View/download PDF

19. Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: A new biomarker for overall survival of patients with malignant diseases

Author

Matsueda, Satoko, Komatsu, Nobukazu, Kusumoto, Kenichi, Koga, Shintaro, Yamada, Akira, Kuromatsu, Ryoko, Yamada, Shingo, Seki, Ritsuko, Yutani, Shigeru, Shichijo, Shigeki, Mine, Takashi, Fukuda, Takaaki, Okamura, Takashi, Okuda, Seiya, Sata, Michio, Honda, Junichi, Kaji, Masahide, Itoh, Kyogo, and Sasada, Tetsuro

Published
2013
Full Text
View/download PDF

43. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours

Author

Galon, Jérôme, Mlecnik, Bernhard, Bindea, Gabriela, Angell, Helen K, Berger, Anne, Lagorce, Christine, Lugli, Alessandro, Zlobec, Inti, Hartmann, Arndt, Bifulco, Carlo, Nagtegaal, Iris D, Palmqvist, Richard, Masucci, Giuseppe V, Botti, Gerardo, Tatangelo, Fabiana, Delrio, Paolo, Maio, Michele, Laghi, Luigi, Grizzi, Fabio, Asslaber, Martin, DʼArrigo, Corrado, Vidal-Vanaclocha, Fernando, Zavadova, Eva, Chouchane, Lotfi, Ohashi, Pamela S, Hafezi-Bakhtiari, Sara, Wouters, Bradly G, Roehrl, Michael, Nguyen, Linh, Kawakami, Yutaka, Hazama, Shoichi, Okuno, Kiyotaka, Ogino, Shuji, Gibbs, Peter, Waring, Paul, Sato, Noriyuki, Torigoe, Toshihiko, Itoh, Kyogo, Patel, Prabhu S, Shukla, Shilin N, Wang, Yili, Kopetz, Scott, Sinicrope, Frank A, Scripcariu, Viorel, Ascierto, Paolo A, Marincola, Francesco M, Fox, Bernard A, and Pagès, Franck

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results